--- title: "CytoDyn (CYDY) news: convertible notes" url: "https://aibio.space/companies/cytodyn/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CYDY convertible notes news: CytoDyn extends two $28.5 million convertible notes by 36 months, cuts interest to 5%. CytoDyn Inc. (OTC: CYDY), United States." --- CYDY CytoDyn Inc. OTC · United States # CytoDyn (CYDY) news CYDY convertible notes news Debt Financing · 2026-03-24 ## [CytoDyn extends two $28.5 million convertible notes by 36 months, cuts interest to 5%](https://aibio.space/news/cytodyn-extends-two-28-5-million-convertible-notes-36-months-cuts/) CytoDyn and the holders of two $28.5 million convertible notes agreed to extend both maturities by 36 months, to April 2029. In return, the company will pay $1,000,000 a month in common stock, and the interest rate falls to 5%. ## Latest CytoDyn news 1. 2025-11-03 Financings [CytoDyn secures $30 million stock purchase commitment from Yorkville Advisors Global](https://aibio.space/news/cytodyn-secures-30-million-stock-purchase-commitment-yorkville/) CytoDyn can sell up to $30 million of common stock to Yorkville Advisors Global over 36 months, at its own discretion and with no warrants attached. The release names no placement agent or counsel, and the annual report says the company will pursue non-dilutive financing in addition to traditional fundraising. 2. 2025-07-25 Financings [CytoDyn files $100,000,000 shelf registration for stock, warrants and units](https://aibio.space/news/cytodyn-files-100-000-000-shelf-registration-stock-warrants-units/) CytoDyn filed a Form S-3 shelf that would let it offer up to $100,000,000 of stock, warrants, subscription rights and units. The stock is quoted on the OTCQB, where it closed at $0.29 on July 24, 2025, and the shelf cannot be used until it takes effect. ## CytoDyn at a glance - **Ticker**: CYDY - **Listing**: OTC - **Country**: United States - **Cash, Aug 31, 2026**: $16.4 million ### Related companies - [ImmunityBio](https://aibio.space/companies/immunitybio/) NASDAQ: IBRX - [Lotus Pharmaceuticals](https://aibio.space/companies/lotus-pharmaceuticals/) OTC: LTUS - [Electra Therapeutics](https://aibio.space/companies/electra-therapeutics/) NASDAQ: ETRA - [Tenaya Therapeutics](https://aibio.space/companies/tenaya-therapeutics/) NASDAQ: TNYA - [Acurx Pharmaceuticals](https://aibio.space/companies/acurx-pharmaceuticals/) NASDAQ: ACXP - [Mirum Pharmaceuticals](https://aibio.space/companies/mirum-pharmaceuticals/) NASDAQ: MIRM - [Oramed Pharmaceuticals](https://aibio.space/companies/oramed-pharmaceuticals/) NASDAQ: ORMP - [Lexicon Pharmaceuticals](https://aibio.space/companies/lexicon-pharmaceuticals/) NASDAQ: LXRX ### Also on OTC - [GOLDENWELL BIOTECH INC.](https://aibio.space/companies/goldenwell-biotech/) GWLL - [ZyVersa Therapeutics](https://aibio.space/companies/zyversa-therapeutics/) ZVSA - [Skinvisible](https://aibio.space/companies/skinvisible/) SKVI - [Cannamerica Brands](https://aibio.space/companies/cannamerica-brands/) CNNXF - [ADM TRONICS UNLIMITED, INC.](https://aibio.space/companies/adm-tronics-unlimited/) ADMT - [PONIARD PHARMACEUT](https://aibio.space/companies/poniard-pharmaceut/) PARD ## What CytoDyn does CytoDyn Inc. is a clinical-stage biotechnology company focused on the clinical development of leronlimab (also referred to as PRO 140), a humanized monoclonal antibody targeting the C-C chemokine receptor type 5 (CCR5). The company's business centers on leronlimab's potential in solid-tumor oncology. Its strategy includes completing the Phase 2 CLOVER study in relapsed/refractory microsatellite stable colorectal cancer and conducting additional studies in other solid-tumor indications, including metastatic triple-negative breast cancer. CLOVER evaluates leronlimab in combination with trifluridine and tipiracil (TAS-102) plus bevacizumab. The company announced successful completion of enrollment in the CLOVER study on April 21, 2026, and on April 27, 2026 completed enrollment and first dosing of the first participant in its Expanded Access Program for triple-negative breast cancer. On June 4, 2026, Natera, Inc. and CytoDyn announced a strategic collaboration under which Natera will assess CLOVER trial samples and provide real-world data analyses. The company says it will need significant additional funding and will pursue non-dilutive financing, including license agreements, co-development and strategic partnerships. The asset was acquired from Progenics, which led its preclinical and early clinical development through 2011. | Product or program | What it is | Stage | |---|---|---| | leronlimab (PRO 140) | Humanized monoclonal antibody targeting CCR5, studied in solid-tumor oncology | Phase 2 (CLOVER); enrollment completed April 21, 2026 | Summarised from the company's [10-K filed Aug 31, 2026](https://www.sec.gov/Archives/edgar/data/1175680/000117568026000014/ck0001175680-20260531.htm). ## CytoDyn annual financials | Line | FY ended May 31, 2026 | FY ended May 31, 2025 | |---|---|---| | Net income (loss) | [-$42.7 million](https://www.sec.gov/Archives/edgar/data/1175680/000117568026000014/) | [$3.7 million](https://www.sec.gov/Archives/edgar/data/1175680/000117568026000014/) | | Cash from operations | [-$17.3 million](https://www.sec.gov/Archives/edgar/data/1175680/000117568026000014/) | [-$8.8 million](https://www.sec.gov/Archives/edgar/data/1175680/000117568026000014/) | | Cash and equivalents | [$11.9 million](https://www.sec.gov/Archives/edgar/data/1175680/000117568026000035/) | [$11.9 million](https://www.sec.gov/Archives/edgar/data/1175680/000117568026000014/) | Latest balance sheet, Aug 31, 2026 (10-Q): cash and equivalents $16.4 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about CytoDyn Has CytoDyn sold convertible notes? Our latest story on this, dated Mar 24, 2026: "CytoDyn extends two $28.5 million convertible notes by 36 months, cuts interest to 5%". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cytodyn-extends-two-28-5-million-convertible-notes-36-months-cuts/). What is the ticker symbol of CytoDyn? CytoDyn Inc. trades under the ticker CYDY on OTC. Where is CytoDyn listed? CytoDyn Inc. is listed on OTC. What is the SEC CIK of CytoDyn? The SEC Central Index Key (CIK) for CytoDyn Inc. is 1175680. Its filings are on SEC EDGAR. How many shares does CytoDyn have outstanding? 1,469,518,000 shares as of 2026-09-30, per the cover page of its 10-Q filed 2026-10-14. Which country or territory is CytoDyn listed under? Our directory records CytoDyn Inc. under United States. What does CytoDyn do? Our directory classifies CytoDyn Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of CytoDyn? The ISIN recorded for CytoDyn Inc. is US23283M1018. Does aibio.space cover CytoDyn? aibio.space lists CytoDyn Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is CytoDyn incorporated? SEC records list its state or country of incorporation as DE. What does CytoDyn develop? CytoDyn Inc. is a clinical-stage biotechnology company focused on the clinical development of leronlimab (also referred to as PRO 140), a humanized monoclonal antibody targeting the C-C chemokine receptor type 5 (CCR5). The company's business centers on leronlimab's potential in solid-tumor oncology. What is leronlimab (PRO 140) from CytoDyn? leronlimab (PRO 140): Humanized monoclonal antibody targeting CCR5, studied in solid-tumor oncology Stage: Phase 2 (CLOVER); enrollment completed April 21, 2026. Is CytoDyn profitable? CytoDyn Inc. reported a net loss of $42.7 million for the fiscal year ended May 31, 2026, and used $17.3 million of cash in operations, per its annual report to the SEC. How much cash does CytoDyn have? $16.4 million in cash at Aug 31, 2026, per its 10-Q. What is the latest CytoDyn (CYDY) stock news? Our latest story on CytoDyn, dated Mar 24, 2026: "CytoDyn extends two $28.5 million convertible notes by 36 months, cuts interest to 5%". CytoDyn and the holders of two $28.5 million convertible notes agreed to extend both maturities by 36 months, to April 2029. In return, the company will pay $1,000,000 a month in common stock, and the interest rate falls to 5%. [Source](https://aibio.space/news/cytodyn-extends-two-28-5-million-convertible-notes-36-months-cuts/). ## Investor discussion: CytoDyn Members talk about CytoDyn (CYDY). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at CytoDyn, newest first. Each line links the filing it comes from. 1. 2026-08-31 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1175680/000117568026000014/ck0001175680-20260531.htm) 2. 2026-04-22 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1175680/000110465926046921/cydy-20250228xs1.htm) 3. 2026-03-24 Financings Reported a financing. SEC Form 8-K (Items 1.01). [Source](https://www.sec.gov/Archives/edgar/data/1175680/000110465926033943/cydy-20260324x8k.htm) 4. 2026-01-09 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1175680/000110465926002335/cydy-20251130x10q.htm) 5. 2025-12-01 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1175680/000110465925117154/cydy-20251123x8k.htm) 6. 2025-11-03 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1175680/000110465925105306/cydy-20251103xex99d1.htm) 7. 2025-07-25 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1175680/000155837025009617/cydy-20250531x10k.htm) 8. 2025-07-25 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1175680/000155837025009619/cydy-20250725xs3.htm) 9. 2025-05-16 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1175680/000155837025007954/cydy-20250514x8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:CYDY on TradingView](https://www.tradingview.com/symbols/OTC-CYDY/). ## SEC filings and registration - **SEC name**: CytoDyn Inc. - **CIK**: 1175680 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CYDY (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: May 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1111 MAIN STREET, SUITE 660, VANCOUVER, WA, 98660 - **Phone**: 360-980-8524 - **Shares outstanding**: 1,469,518,000 as of 2026-09-30 (10-Q filed 2026-10-14) - **Former names**: CYTODYN INC; REXRAY CORP ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1175680/000117568026000038/ck0001175680-20261016.htm) filed 2026-10-19 - [10-Q](https://www.sec.gov/Archives/edgar/data/1175680/000117568026000035/ck0001175680-20260831.htm) filed 2026-10-14 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1175680/000117568026000026/ck0001175680-20260928.htm) filed 2026-09-28 - [S-3](https://www.sec.gov/Archives/edgar/data/1175680/000117568026000024/ck0001175680-20260925.htm) filed 2026-09-25 - [10-K](https://www.sec.gov/Archives/edgar/data/1175680/000117568026000014/ck0001175680-20260531.htm) filed 2026-08-31 - [8-K](https://www.sec.gov/Archives/edgar/data/1175680/000117568026000002/ck0001175680-20260430.htm) filed 2026-04-30 - [S-1](https://www.sec.gov/Archives/edgar/data/1175680/000110465926046921/cydy-20250228xs1.htm) filed 2026-04-22 - [10-Q](https://www.sec.gov/Archives/edgar/data/1175680/000110465926040687/cydy-20260228x10q.htm) filed 2026-04-08 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001175680), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details CytoDyn Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker CYDY, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: CytoDyn Inc. - **Ticker**: CYDY - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US23283M1018 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-CYDY/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/cytodyn/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "CytoDyn (CYDY) news: convertible notes", 2026-10-31, https://aibio.space/companies/cytodyn/